SpeeDx launches PlexPrime^® SARS-CoV-2 Genotyping research reagents

SpeeDx have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC). The rapid development of PlexPrime^® SARS-CoV-2 Genotyping research reagents will support investigations of the range of emerging and circulating COVID-19 VOC.

“Our unique technology excels in mutation detection applications and can readily be applied to variants reported in the SARS-CoV-2 sequence databases,” said Elisa Mokany, SpeeDx Chief Technology Officer.